RecipientAmountDeal/Technology HighlightLead InvestorDeal TypeCountry
Kite Pharma$11,900 millionCAR T Therapy Candidate, Axicabtagene CiloleucelGilead AcquisitionUnited States
IFM Therapeutics$2,300 millionPreclinical programs focused on enhancing the innate immune response for treating cancer Bristol-Myers SquibbAcquisitionUnited States
NxStage$2,000 millionProduct portfolio of medical devices for use in home dialysis and in the critical care settingFresenius Medical CareAcquisitionUnited States
PharMerica Corporation$1,400 millionPharMerica Corporation is a leading provider of pharmacy services. PharMerica serves the long-term care, hospital pharmacy management services, specialty home infusion and oncology pharmacy markets.KKR with Walgreens Boots AllianceAcquisitionUnited States
Roivant Sciences$1,100 millionRoivant focuses on developing and commercializing novel therapies through 'Vants' subsidiariesSoftbank Vision FundEquity investmentSwitzerland
Roche>$1,000 millionWorldwide rights to develop and commercialize lebrikizumabDermiraLicensingSwitzerland
Envigo International Holdings$924 millionEnvigo, with over 80 years of experience, is a leading provider of non-clinical R&D services and research models offering mission-critical products and services to the life sciences, chemical, crop protection, and academic markets. Avista Healthcare Public Acquisition Corp. Merger, Envigo will become a wholly-owned subsidiary of AHPACUnited States
WuXi Biologics (In-partnership with Gloria Pharmaceuticals)$816 millionExclusive development and commercialization rights of GLS-010 in North America, Europe, Japan and certain other territoriesArcus BiosciencesLicensingChina
Symphony$530 millionHealth data and analyticsPRA Health SciencesPurchaseUnited States
InfaCare$425 millionLead drug designed to treat hyperbilirubinemia in NewbornsMallinckrodtBuyoutUnited States
AstraZeneca$400 millionCo-develop the alpha-synuclein antibody. Alpha-synuclein is a protein found in high levels in the Lewy bodies that form in the nerve cells of Parkinson’s patients.Takeda Co-developmentUnited Kingdom
Spectrum Inc.$359 millionThe merger is expected to accelerate the growth of Repligen's filtration business, provide access to new customers, and greatly expand its commercial footprint, strengthening Repligen's position as a leader in single-use and continuous manufacturing technologies for bioprocessing.Repligen CorporationAcquisitionUnited States
Calimmune$325 millionDevelopment of ex vivo hematopoietic stem cell (HSC) gene therapy. Additionally, CSL Behring will acquire two unique proprietary platform technologies, Select+™ and Cytegrity™. These technologies are designed to address some of the major challenges currently associated with the commercialization of stem cell therapy, including the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy and tolerability.CSL BehringAcquisition, milestone payments over a period currently anticipated to be around eight years or more following the closing of the transaction.United States
Aptuit$300 millionBroadening expertise in the respiratory and fibrosis therapeutic areas, while filling the service gap between preclinical and in-human studiesEvotecAcquisitionUnited States
CellAct > $250 millionThe worldwide development and commercialization of smart chemotherapy CAP7.1. CAP7.1 is a novel ‘smart chemotherapy’ that has the potential to treat orphan diseasendesignated biliary tract cancer for which there are no second line treatment options.MundipharmaProduct AcquisitionGermany
Forma Therapeutics$195 millionNew drugs focused on protein homeostasis, inflammation/immunology and neurodegenerationCelgeneUpfront paymentUnited States
ImmunoGen$175 millionHematology-related antibody-drug conjugate (ADC) programsJazz Pharmaceuticals plcUpfront paymentUnited States
ClearCorrect, LLC$150 millionClearCorrect’s role in driving the rapidly-growing clear aligner market. It comes as part of a new initiative by Straumann to enter the orthodontic market and leverage the power of digital technology to deliver total orthodontic solutions.Straumann GroupAcquisitionUnited States
SK Capital$110 millionPerrigo API is a “proven industry leader with strong innovation and manufacturing capabilities and a quality and customer-centric culture.” As part of the deal with SK, both Perrigo and SK will enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The deal is expected to close by the end of 2017. PerrigoAcquisitionUnited States
Confluence $100 millionDiscovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancerAclaris Acquisition United States
Dimension Therapeutics$86 millionGain the rights to DTX301 and DTX401. DTX301 is the more advanced of the candidates, having already moved into a phase 1/2 trial in patients with late-onset ornithine transcarbamylase deficiency.Regenxbio Product AcquisitionUnited States
Homology Medicines$83.5 millionAttempting to leverage homologous recombination and adeno-associated virus (AAVs) vectors to create new therapies for rare genetic diseaseDeerfield ManagementSeries B fundingUnited States
Zealand Pharma$77 millionThe diabetes drug lixisenatide to Sanofi while it concentrates on its lead development program for glepaglutide, a GLP-2 drug that has been in mid-stage development for short bowel syndrome.SanofiOutlicensed (IPO)Denmark
Aptevo Therapeutics$74.5 millionThree marketed hyperimmune products, WinRho® SDF, HepaGam B®, and VARIZIG®Saol TherapeuticsAcquisitionUnited States
ARMO BioSciences$67 millionAM0010 (pegilodecakin), a long-acting pegylated form of recombinant human Interleukin-10 (IL-10)Qiming Venture PartnersSeries C-1 private financingUnited States
Amplyx Pharmaceuticals$67 millionNovel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infectionsSofinnova Venture PartnersSeries C financingUnited States
CF PharmTech$65 millionDevelopment of metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal productsSDIC Fund Management Corporation LimitedSeries D financingChina
Apellis Pharmaceuticals$60 millionThe proceeds of the financing will be used to initiate Phase 3 trials with APL-2 in paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder, and advance development in other indications. VariousSeries E financingUnited States
Hangzhou Just Biotherapeutics$57 millionDedicated to developing global antibody and recombinant protein bio-therapeuticsTemasekSeries B financingUnited States
Milestone Pharmaceuticals$55 millionEtripamil, a novel, potent, short-acting calcium channel blocker developed as a fast-acting nasal spray that can be administered by the patient to terminate paroxysmal supraventricular tachycardia (PSVT, a heart condition) episodes wherever and whenever they occur.Novo Holdings A/SSeries C financingCanada
Karius$50 millionKarius’ Digital Culture™ test applies advanced sequencing and analytics for the broad and rapid detection of microbial cell-free DNA through a standard blood drawData Collective (DCVC) and Lightspeed Venture PartnersSeries A equity financingUnited States
aTyr Pharma$46 millionThe biotech is focused on what it believes will be a new class of proteins called physiocrines. The scientific founder is Paul Schimmel out of Scripps. Their lead drug is Resokine, now in three clinical programs for severe, rare myopathies with an immune component.Viking Global InvestorsEquity dealUnited States
Cerecore$45 millionLate-stage program for an inhaled version of ketamine, a horse tranquilizer that has demonstrated dramatic responses for quickly lifting depression and suicidal thinking — and which also has major psychotropic side effects.Johnson & JohnsonOutlicensedUnited States
Cyalume Technologies Holdings$45 millionCyalume produces specialty chemicals, pharmaceutical components, designs and manufactures unique related products and does sub-contract manufacturing of components for use in pharmaceutical, medical, commercial and military markets. Arsenal Capital PartnersAcquisition United States
Insilico Medicine$42.7 millionArtificial intelligence technology can aid in the drug discovery processGlaxoSmithKline PartnershipUnited States
Ionis Pharmaceuticals $40 millionPricing approval of SPINRAZA® (nusinersen) in JapanBiogenMilestone paymentUnited States
Mazor Robotics$40 millionMazor X system, Core of the Surgical Assurance Platform for Spine SurgeryMedtronicThird tranche investmentIsrael
AbleTo$36.6 millionTechnology-enabled behavioral health care. AbleTo's structured therapy programs strengthen medical recovery and self-care among members with chronic or complex clinical needs. A proprietary platform connects individuals and their care teams with AbleTo licensed providers who deliver weekly sessions by phone or video supported by an integrated digital experience. Bain Capital VenturesSeries D fundingUnited States
UNITY Biotechnology$35 millionUNITY is developing a new class of therapies for diseases of aging called senolytic medicinesINVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha LimitedSeries B financingUnited States
Atreca $35 millionThis funding enables us to accelerate the acquisition of immune response data central to cancer immunotherapy and to expand and advance our pipeline of novel antibody therapeutics based on those data.Wellington ManagementSeries B fundingUnited States
Good Start Genetics and CombiMatrix$33 millionGood Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers. CombiMatrix Trusted for Advanced DNA Diagnostics by Reproductive Health and Pediatric Specialists.Invitae AcquisitionUnited States
Dr. Reddy's$32.5 millionDevelopment, manufacturing and commercialization rights to the drug, a topical corticosteroid called DFD-06 that is administered twice daily as a cream and is also in phase 2 testing for psoriasis in children and adolescents.Encore Product Out-LicensingIndia
Xoma$31 millionAnti-IL-1 beta allosteric monoclonal antibody, a price that reflects the battering its prospects took as a late-phase clinical development program unraveledNovartisUpfront paymentUnited States
SetPoint Medical$30 millionA novel proprietary bioelectronic medicine platform using a small implanted device that activates the body’s natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.SetPoint’s existing investors, including NEA, Morgenthaler, Medtronic, Boston Scientific, Topspin, Action Potential Venture Capital and others.Series D financingUnited States
RareCyte, Inc.$30 millionRareCyte's integrated rare cell platform, based on the AccuCyte® and CyteFinder® product lines, has been adopted by leading academic medical institutions and biopharma companies to advance both pre-clinical research and clinical applications.5AM VenturesPrivate financingUnited States
MedGenome$30 millionMedGenome's OncoPept™ suite of cancer immunotherapy biomarker solutionsSequoia India and Sofina s.a.Series C financingIndia
Ethris $29 millionRespiratory diseases and secure the option to license the fruits of the collaborationAstraZeneca Upfront paymentGermany
EagleDream Health Inc.$26 millionEagleDream Health Inc. is a healthcare software analytics company that delivers a SaaS-based, comprehensive, and integrated solution that spans the entire clinical, financial, and administrative spectrum.NextGen Healthcare Information Systems, LLCAcquisitionUnited States
CytoBioscience$24.6 millionBroadening our company’s business and brings immediate and meaningful revenue. It also brings a host of important medical center customers and relationships, including a Who’s Who in pharmaceutical product development, that we can leverage to increase awareness of the STREAMWAY System and generate sales.Skyline MedicalMergerGermany
Stride Health$23.5 millionStride Health helps workers predict out-of-pocket healthcare costs, lower the cost of prescription drugs, and navigate complex insurance claimsF-Prime Capital PartnersSeries B financingUnited States
Vicarius Pharma AG$22 millionInnovator companies retain strategic control over R&D, plus the flexibility to recover at any time the asset and dedicated organization built by VicariusPrivate investorsSeries A financingSwitzerland
ZingBox$22 millionZingBox provides hospitals, companies and manufacturing facilities with Internet of Things (IoT) security software that helps ensure service deliveryDell Technologies Capital and TriventuresSeries B fundingUnited States
Torque Therapeutics$21 millionNovel Cancer Cellular TherapiesUndisclosedSeries A financingUnited States
vivoPharm $21 millionDeal will boost Cancer Genetics position “as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechnology and pharmaceutical companies.”Cancer GeneticsEquity financingAustralia
Antengene$21 millionOngoing effort to further expand its product portfolio of both pipeline assets at clinical development stage and mature productsVC Qiming Venture PartnersSeries A financingChina
Brains On-Line$21 millionBrains On-Line provides preclinical contract research services in CNS and offers in vivo efficacy and pharmacokinetics testing for analysis of drugs in the brainCharles RiverAcquisitionNetherlands
Neuros Medical, Inc.$20 millionAltius® High Frequency Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of conditions, including amputation pain, post-surgical pain, migraine, and trigeminal neuralgia.U.S. Venture PartnersSeries AA venture capital financingUnited States
Roka Bioscience$17.5 millionRoka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced that it has entered into an asset purchase agreement with Rokabio, Inc.Rokabio, Inc.(Subsidiary of Institute For Environmental Health, Inc)Assest Purchase AgreementUnited States
BrainScope Company$16 millionBrainScope One,a revolutionary medical technology that gives urgent care physicians and staff greater assurance to objectively assess the full spectrum of brain injury, including concussionDBL PartnersEquity financingUnited States
Colorescience$15 millionA robust portfolio of clinically-tested products that blur the lines between skincare and cosmetics while protecting skin against UV exposure and environmental aggressors1315 Capital, L.P.Series C Preferred StockUnited States
VentureMed Group, Inc.$15 millionNext-generation endovascular products to treat patients suffering from peripheral artery disease (PAD)Endeavour VisionSeries B equity financingUnited States
NeoSync $13 millionTo support a registration trial of its NeoSync-EEG Synchronized transcranial magnetic stimulation technologyValiance Life ScienceSeries D financingUnited States
Aytu BioScience, Inc.$11.8 millionNatesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.VariousPrivate placement of equity unitsUnited States
Alzeca Biosciences, Inc.$11 millionNovel, proprietary, targeted MRI imaging agents for the early diagnosis of Alzheimer’s disease and other neurodegenerative disordersPeter J. Werth, Jr., President and Chief Executive Officer of Chemwerth, Inc., and Navneet Puri, Ph.D., Founder and Chief Executive Officer of Nevakar, LLCSeries A financingUnited States
Regenxbio$10 millionThe gene therapy specialist's adeno-associated virus (AAV) based vector technology NAV AAV9 for PD and other neurodegenerative disordersOrbiMedNew nonprofit foundation to create Prevail TherapeuticsUnited States
Eloxx Pharmaceuticals$8 millionELX-02, a designer aminoglycoside with unique pharmacological properties scaffold that has been developed and optimized as a translation read-through inducing drug through intensive medicinal chemistry efforts over the past 10 years.LSPSeries C financingIsrael
Freenome$7 million A combination of machine learning, biology and computer science to create simple and effective disease screening assays.Section 32Extension to its previously announced Series A fundingUnited States
Limelight Health$7 millionLimelight Health's first product, QuotePad, helps its users access on-demand health plan rate data and price quotes, auto-generate custom sales proposals, and provides a single platform for decision support and electronic enrollments.MassMutual VenturesSeries B financingUnited States
LVL Technologies, Inc.$6.75 millionBringing accuracy of medical device technologies to the consumer wearables market through a combination of proprietary sensors and advanced machine learning algorithms.Samsung Catalyst FundSeries A financingUnited States
Buoy Health$6.7 millionBuoy Health is a health technology company that develops digital tools to help people from the moment they get sick start their care on the right footF-Prime Capital PartnersSeries A financingUnited States
Symphony Ventures$4.5 millionConsulting, implementation and managed services to enterprise clients looking to automate operational processes that are manual, repetitive, complex and time consuming through RPA and Intelligent Automation solutions.LivingbridgeSeries A financingUnited Kingdom
HERB$4.1 millionDedicated to bringing high-quality cannabis content to its rapidly growing audienceLerer Hippeau VenturesSeed FundingCanada
Access Vascular$3.7 millionHydroPICC™, a superior peripherally inserted central catheterangelMDInvestment funding roundUnited States
PriorAuthNow$3.6 millionA platform for connecting the healthcare landscape using prior authorization (PA) automationNCT Ventures and with participation from Detroit Venture Partners (DVP)Investment funding roundUnited States
ExplORer Surgical$3 millionPlatform for intraoperative surgical and interventional procedure workflow management and analyticsAphelion CapitalSeries A financingUnited States
Cardax, Inc.$2.75 millionZanthoSyn, a pure and highly absorbed form of astaxanthin, marketing campaignUndisclosedInvestment subscriptionsUnited States
Amcure$2 millionLead Candidate AMC303 - inhibits CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON) involved in tumor growth, angiogenesis and the development and regression of metastases.German Ministry of Education and Research (BMBF)GrantGermany
Alyria skincare line of products from Sanofi Consumer Health$1.7 millionAlyria is a high-quality, non-prescription, line of medical skincare products sold into medical spasCrescita Therapeutics Inc.AcquisitionCanada
MabVax Therapeutics Holdings, Inc.$1.3 millionAntibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors.UndisclosedSeries J Convertible Preferred StockUnited States
ProMIS Neurosciences Inc.$1.07 millionProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.VariousPrivate PlacementCanada
Crescita Therapeutics$1.0 millionMultiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skinBloom Burton FundsConvertible debenture financing Canada
Glance Technologies Inc.$1 millionCreate and provide the technology backbone for the Active Pay appActive Pay Distribution Inc.LicensingCanada
Natrix SeparationsUndisclosedHydrogel membrane products for single-use chromatographyMerck KGaAAcquisitionCanada
Viroclinics Biosciences B.V.UndisclosedGlobally preferred institute for virology testingParcom CapitalAcquisitionNetherlands
Daiichi Sankyo Company, Limited UndisclosedDS-5010, a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET rearrangements and activating mutations are associated with several types of cancer, including non-small cell lung cancer, colorectal cancer and thyroid cancer.Boston Pharmaceuticals, Inc.Worldwide licensing agreementJapan
Gallant Custom Laboratories IncUndisclosedOnly Canadian company authorized by the Canadian Food Inspection Agency (CFIA) to manufacture autogenous viral and bacterial vaccinesIDT BiologikaAcquisitionCanada
Accuity Delivery Systems LLCUndisclosedAccuity is a revenue cycle management business that provides clinical documentation improvement (CDI), coding and quality assurance and provider education services to its hospital clientsMTS Health Investors, LLCInvestmentUnited States
CureMatchUndisclosedCureMatch's Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profileSerra VenturesBridge round to Series A financingUnited States
EnableComp LLCUndisclosedEnableComp is a healthcare technology enabled services company that partners with healthcare providers to maximize reimbursement from workers' compensation payersPrimus CapitalInvestmentUnited States
Plex PharmaceuticalsUndisclosedPlex has developed a novel co-drug molecule, in which two drug molecules are delivered in the form of a single conjugate and later released as two single-agents, each targeting the tumor site(s).Collidion Inc.80% equity stakeUnited States
Macrophage Pharma Limited UndisclosedESM™ technology platform, which is designed to deliver small molecule drugs to macrophages in a highly selective manner, activating the body's natural immune system to fight cancer. The Company's lead p38MAPi program is focused on a novel macrophage-targeting p38 MAPK inhibitor. Merck Ventures joins the existing investor syndicate of CRT Pioneer Fund (CPF), Novo Holdings A/S and Aglaia Biomedical Ventures BVSeries A financingUnited Kingdom
Asterand BioscienceUndisclosedProvider of high quality, well-characterized human tissue and human tissue-based research solutions to drug discovery scientistsBioreclamationIVTAcquisitionUnited States
CuroverseUndisclosedCuroverse software is used by industry leaders such as the Wellcome Trust Sanger Institute to manage, process and share petabytes of genomic and biomedical data as well as facilitate AI and machine learning.Veritas GeneticsAcquisitionUnited States
PfizerUndisclosedSterile manufacturing facility located in Liscate, ItalyAvara Pharmaceutical ServicesAcquisitionItaly
Elligo Health ResearchUndisclosedImprove clinical trial enrollment by helping physicians conduct clinical studies in their own clinicsAllscripts PartnershipUnited States
Takeda UndisclosedCo-develop drugs (TAK-671) against diseases including pancreatitisSamsung BioepisPartnershipJapan
Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center, and Synergie Lyon CancerUndisclosedAssess Sigma1 in disease and assess the activity of Context’s inhibitors of the proteinContext TherapeuticsCollaborationUnited States
Stanford UniversityUndisclosedTransform novel Stanford research into next-generation treatments for diseasesTakeda AgreementUnited States
Aduro BiotechUndisclosedExclusive license for uses of DNA-encoded library (DEL) design, synthesis and screening to discover novel small-molecule leadsHitGen CollaborationNetherlands
Shattuck LabsUndisclosedCombination immunotherapy with a single productTakeda CollaborationUnited States
CempraUndisclosedLate-phase development of anti-infective drugsMelinta TherapeuticsMergerUnited States
Galena BiopharmaUndisclosedSeeks to guide its Wilms tumor 1 (WT1)-targeting drug through phase 3 trials in acute myeloid leukemia (AML) and mesotheliomaSellas Life SciencesMergerUnited States
Yale UniversityUndisclosedTo develop and study a genetic model of WHIM syndromeX4 PharmaceuticalsCollaboration United States
ROC IT SolutionsUndisclosedTo capture, process and exchange serialized product data across a digital supply chain network and also more effectively manage warehouse product inventory at the “edge” of the supply chainTraceLink, Inc. AcquisitionUnited States
J+D Labs Pharma Manufacturing, Inc.UndisclosedFocus on investing in and growing industry-leading vitamin, mineral, and supplement companiesCaptek Softgel International, Inc.AcquisitionUnited States
TearScience, Inc.UndisclosedFocus on treating meibomian gland dysfunctionJohnson & Johnson Vision Care, Inc.AcquisitionUnited States
Endeavor Clinical TrialsUndisclosedTo explore clinical research, specializing in post-operative pain, neuropathic pain, podiatry, and vaccine researchEvolution Research Group, LLC AcquisitionUnited States
Senosis HealthUndisclosedTo use the existing functions of smartphones to diagnose various ailmentsGoogleBuyoutUnited States
Aduro LaserUndisclosedProvides additional resources and synergies to provide solutions to our customers on a larger scaleResonetics (Supported by Sverica Capital Management LLC)AcquisitionUnited States